Welcome to our dedicated page for Genenta Science Spa SEC filings (Ticker: GNTA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Genenta Science S.p.A. filings document a foreign private issuer reporting on Form 6-K, with disclosures incorporated by reference into its Form F-3 registration statement when specified. The record covers material events, shareholder voting matters, capital-structure updates, operating and financial results, and clinical or regulatory disclosures for its biotechnology platform and Temferon program.
The filings also document governance and corporate-structure actions, including the approved expansion of the company’s corporate purpose to sectors covered by Italian Golden Power legislation, board changes, listing-compliance notices, material agreements, and decisions to streamline subsidiaries and finance-function arrangements as Genenta pursues an Italy- and Europe-focused industrial aggregator strategy.
Genenta Science S.p.A. Chief Financial Officer Richard B. Slansky filed an initial ownership report showing a mix of stock options, ordinary shares and American Depositary Shares. He holds several option grants over ADSs with exercise prices of $4.76, $3.08, $4.36 and $1.48, vesting over multi‑year schedules and expiring between 2032 and 2035. In addition, he directly owns 19,947 ordinary shares and 2,200 ADSs, with each ADS representing one ordinary share.
GNTA is amending its at-the-market program so it may issue and sell American Depositary Shares with aggregate sales proceeds of up to $26,441,569 from time to time under an existing Sales Agreement with Virtu Americas LLC and Rodman & Renshaw LLC. The prior authorization allowed up to $29,696,999, of which ADSs generating $3,255,430 in gross proceeds have already been sold. Net proceeds from any future sales are intended for general corporate purposes, working capital and potential acquisitions or investments. The ADSs trade on Nasdaq under the symbol GNTA, with a last reported sale price of $1.30 per ADS on January 26, 2026.
Genenta Science S.p.A. investor Pierluigi Paracchi reports a 9.8% ownership stake in the company’s ordinary shares as of January 25, 2026. He beneficially owns 2,302,516 ordinary shares, including 27,000 American depository shares, with sole voting and dispositive power over the entire amount and no shared power.
The percentage is calculated based on 23,432,183 Genenta ordinary shares outstanding as of the same date, indicating that Paracchi remains a significant but non‑controlling shareholder.
Genenta Science S.p.A. outlines a major strategic shift alongside governance and legal updates. The company plans to change its corporate name to Saentra Forge S.p.A. and its Nasdaq ticker to SAEN, subject to shareholder approval at an extraordinary meeting scheduled for March 25–26, 2026.
The business intends to expand from its existing Temferon-focused biotech activities into acting as a biotech, defense, aerospace and national security industrial consolidator under Italy’s Golden Power regime. As part of this strategy, it signed an investment agreement to buy an initial 19.5% stake in A.T.C. S.r.l. for €1.275 million, with the ability to increase ownership up to 51% over multiple closings for a total of €5.1 million, contingent on turnover and EBITDA milestones and maintenance of key licenses. The deal includes a put option allowing Genenta to sell back its stake if licenses are lost for at least two months or performance falls below specified thresholds, at a price equal to its total investment.
Genenta also entered a five-year, automatically renewable shareholders’ agreement with Fondazione Praexidia, a foundation linked to Italian institutional and defense figures, after its CEO donated 3,000 ADS to the foundation. They will consult on transactions subject to Italian Golden Power rules, and both parties are subject to a lock-up on their shares with defined exceptions, while the foundation receives no management powers. Separately, the company has started legal proceedings in Milan against Fondazione Enea Tech Biomedical related to a EUR 20 million convertible bond loan agreement signed in March 2025, under which Genenta has so far received EUR 7.5 million, seeking to have the agreement declared null and to obtain damages.
Genenta Science S.p.A. is launching a major strategic shift from a pure biotech focus into becoming a next‑generation industrial consolidator in Italian national‑security regulated sectors, including defense, aerospace, cybersecurity, and biosecurity. The company plans to change its corporate name to Saentra Forge S.p.A. and adopt a new Nasdaq ticker symbol SAEN, subject to shareholder approval at a meeting scheduled for March 25‑26, 2026.
Execution has started with a binding agreement to fund defense‑sector company ATC via performance‑based, staged capital increases, with a goal of obtaining a controlling position. ATC projects 2026 revenue of approximately €4.0 million and 2027 revenue around €9.0 million and expects EBITDA above €2.0 million in 2026 with a planned doubling in 2027, while operating with net cash and no bank debt.
The Praexidia Foundation, a sovereign‑aligned private foundation, has become a long‑term shareholder via a donation of shares from the CEO and entered into a shareholders’ agreement featuring consultation rights and a renewable five‑year lock‑up. Genenta is seeking to advance its cell therapy platform through partnerships rather than internally funding all trials and expects preliminary, unaudited cash, cash equivalents, and marketable securities of approximately $33 million at December 31, 2025, up from $17.7 million at June 30, 2025, primarily due to a registered direct offering.
Genenta Science S.p.A. (GNTA) reported outcomes from its Ordinary and Extraordinary Shareholders’ Meeting. Directors Armon R. Sharei, Francesco Galimi, and CEO Pierluigi Paracchi will continue on the Board, and two new directors were appointed: Miguel Maria Mutti, a senior pharma and investment banking executive, and Giacomoantonio Paracchi, a business lawyer and brother of the CEO.
Shareholders approved an amendment to Article 4 of the by-laws to extend the corporate purpose to sectors covered by Italy’s Golden Power legislation. Effectiveness is expressly conditioned on no shareholder exercising the statutory withdrawal right; a single valid withdrawal makes the amendment ineffective and does not trigger share liquidation. The withdrawal right must be exercised by registered letter within 15 days of registration of the resolution, i.e., by about November 15, 2025.
The amended by-laws were filed as Exhibit 3.1. The filing notes a recent capital increase with 4,285,715 new shares and that updated by-laws reflecting share capital will be filed within 30 days from execution.
Genenta Science S.p.A. (GNTA) is conducting a registered direct primary offering of 4,285,715 ADSs at $3.50 per ADS, for gross proceeds of $15,000,002.50. After placement agent fees of $900,000.15 and estimated expenses, the company expects net proceeds of approximately $13.8 million, which it intends to use for working capital and general corporate purposes. The ADSs are listed on Nasdaq under “GNTA,” and delivery is expected on or about October 28, 2025.
Maxim Group LLC and Rodman & Renshaw LLC are acting as placement agents on a reasonable best efforts basis. The company reports as adjusted net tangible book value of $1.16 per ADS, implying immediate dilution of $2.34 per ADS to new investors. Ordinary Shares outstanding are expected to be 23,432,183 after the offering. The last reported GNTA price on October 24, 2025 was $6.20 per ADS.
Genenta Science S.p.A. (GNTA) entered into a registered direct offering of 4,285,715 ADSs at $3.50 per ADS, for gross proceeds of approximately $15.0 million, expected to close on or about October 28, 2025 subject to customary conditions. Each ADS represents one ordinary share.
The company plans to use net proceeds for working capital and general corporate purposes. The sale is being made under a prospectus supplement to Genenta’s effective Form F-3 shelf.
Maxim Group LLC (lead) and Rodman & Renshaw LLC (co-placement agent) are acting as placement agents; Genenta will pay a 6.0% cash fee on aggregate gross proceeds and up to $75,000 for expenses. For 90 days after closing, the company, and separately its officers and directors under lock-up agreements, agree to restrictions on issuing or selling company securities, with limited exceptions. The company also agreed not to conduct variable rate transactions for six months.
Genenta Science S.p.A. (GNTA) reported outcomes from its April 29, 2025 Annual Ordinary Shareholders’ Meeting. Shareholders approved the statutory financial statements for the year ended December 31, 2024, audited by Revicom.
They appointed three directors effective April 29, 2025, adding Dr. Francesco Galimi as a new member. Armon R. Sharei, Ph.D. continued on the Board, and Pierluigi Paracchi continued as Chairman. The term of office for each newly appointed director is one year.
The aggregate annual directors’ compensation was set at €105,000. On April 30, 2025, the directors appointed Mr. Paracchi as Chief Executive Officer and allocated annual compensation of €45,000 for the CEO and €30,000 for each of Dr. Galimi and Dr. Sharei.
Genenta Science S.p.A. filed a Form 6-K to provide its unaudited consolidated financial statements as of June 30, 2025 and for the six months ended June 30, 2025. These interim results give a mid-year view of the company’s financial position and performance.
The filing also includes Management’s Discussion and Analysis of Financial Condition and Results of Operations for the same six-month period, offering management’s narrative on the numbers. The Form 6-K is incorporated by reference into Genenta’s existing shelf registration statement on Form F-3, linking these updated financials to potential future securities offerings.